Bank of America’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-150,198
| Closed | -$457K | – | 8693 |
|
|
2024
Q4 | $457K | Sell |
150,198
-37,234
| -20% | -$162K | ﹤0.01% | 5616 |
|
|
2024
Q3 | $973K | Buy |
187,432
+7,481
| +4% | +$37.2K | ﹤0.01% | 5072 |
|
|
2024
Q2 | $462K | Sell |
179,951
-324,725
| -64% | -$1.11M | ﹤0.01% | 5389 |
|
|
2024
Q1 | $2.48M | Buy |
504,676
+296,003
| +142% | +$1.75M | ﹤0.01% | 4281 |
|
|
2023
Q4 | $1.83M | Buy |
208,673
+87,764
| +73% | +$719K | ﹤0.01% | 4502 |
|
|
2023
Q3 | $1.39M | Sell |
120,909
-161,237
| -57% | -$3.1M | ﹤0.01% | 4568 |
|
|
2023
Q2 | $7.14M | Sell |
282,146
-7,854
| -3% | -$245K | ﹤0.01% | 3043 |
|
|
2023
Q1 | $9.34M | Buy |
290,000
+114,091
| +65% | +$3.56M | ﹤0.01% | 2904 |
|
|
2022
Q4 | $3.25M | Sell |
175,909
-253,562
| -59% | -$5.8M | ﹤0.01% | 3805 |
|
|
2022
Q3 | $11.6M | Buy |
429,471
+324,549
| +309% | +$6.58M | ﹤0.01% | 2459 |
|
|
2022
Q2 | $1.45M | Buy |
104,922
+70,060
| +201% | +$1.08M | ﹤0.01% | 4580 |
|
|
2022
Q1 | $680K | Sell |
34,862
-76,675
| -69% | -$1.16M | ﹤0.01% | 5582 |
|
|
2021
Q4 | $1.82M | Buy |
111,537
+41,017
| +58% | +$684K | ﹤0.01% | 4657 |
|
|
2021
Q3 | $1.97M | Buy |
70,520
+1,195
| +2% | +$34.1K | ﹤0.01% | 4462 |
|
|
2021
Q2 | $2.06M | Sell |
69,325
-1,985
| -3% | -$57.3K | ﹤0.01% | 4290 |
|
|
2021
Q1 | $1.99M | Buy |
71,310
+10,702
| +18% | +$296K | ﹤0.01% | 4263 |
|
|
2020
Q4 | $1.72M | Sell |
60,608
-28,021
| -32% | -$726K | ﹤0.01% | 4086 |
|
|
2020
Q3 | $2.23M | Buy |
88,629
+31,580
| +55% | +$828K | ﹤0.01% | 3592 |
|
|
2020
Q2 | $1.39M | Buy |
57,049
+3,186
| +6% | +$62.9K | ﹤0.01% | 3882 |
|
|
2020
Q1 | $797K | Buy |
53,863
+22,192
| +70% | +$459K | ﹤0.01% | 4173 |
|
|
2019
Q4 | $514K | Sell |
31,671
-10,725
| -25% | -$166K | ﹤0.01% | 4995 |
|
|
2019
Q3 | $551K | Sell |
42,396
-199
| -0.5% | -$2.44K | ﹤0.01% | 5013 |
|
|
2019
Q2 | $553K | Sell |
42,595
-39,728
| -48% | -$501K | ﹤0.01% | 4990 |
|
|
2019
Q1 | $1.3M | Buy |
82,323
+33,270
| +68% | +$577K | ﹤0.01% | 4314 |
|
|
2018
Q4 | $987K | Sell |
49,053
-33,547
| -41% | -$739K | ﹤0.01% | 4413 |
|
|
2018
Q3 | $2.05M | Sell |
82,600
-38,157
| -32% | -$1.04M | ﹤0.01% | 3960 |
|
|
2018
Q2 | $3.31M | Buy |
120,757
+90,248
| +296% | +$2.71M | ﹤0.01% | 3547 |
|
|
2018
Q1 | $940K | Buy |
30,509
+21,026
| +222% | +$677K | ﹤0.01% | 4428 |
|
|
2017
Q4 | $339K | Sell |
9,483
-490
| -5% | -$14.1K | ﹤0.01% | 5154 |
|
|
2017
Q3 | $275K | Buy |
9,973
+4,220
| +73% | +$102K | ﹤0.01% | 5247 |
|
|
2017
Q2 | $151K | Sell |
5,753
-1,494
| -21% | -$33.3K | ﹤0.01% | 5433 |
|
|
2017
Q1 | $151K | Buy |
7,247
+1,651
| +30% | +$33.9K | ﹤0.01% | 5441 |
|
|
2016
Q4 | $116K | Buy |
5,596
+3,079
| +122% | +$51.6K | ﹤0.01% | 5561 |
|
|
2016
Q3 | $41K | Sell |
2,517
-1,075
| -30% | -$15.6K | ﹤0.01% | 5809 |
|
|
2016
Q2 | $49K | Buy |
3,592
+1,925
| +115% | +$34K | ﹤0.01% | 5844 |
|
|
2016
Q1 | $29K | Sell |
1,667
-14,259
| -90% | -$290K | ﹤0.01% | 5999 |
|
|
2015
Q4 | $544K | Buy |
15,926
+14,670
| +1,168% | +$509K | ﹤0.01% | 4762 |
|
|
2015
Q3 | $38K | Sell |
1,256
-1,200
| -49% | -$36.4K | ﹤0.01% | 6061 |
|
|
2015
Q2 | $79K | Buy |
2,456
+1,428
| +139% | +$36.7K | ﹤0.01% | 5723 |
|
|
2015
Q1 | $22K | Sell |
1,028
-3,372
| -77% | -$58.3K | ﹤0.01% | 6008 |
|
|
2014
Q4 | $75K | Buy |
4,400
+3,031
| +221% | +$52.9K | ﹤0.01% | 6089 |
|
|
2014
Q3 | $26K | Buy |
1,369
+32
| +2% | +$834 | ﹤0.01% | 6906 |
|
|
2014
Q2 | $45K | Buy |
1,337
+337
| +34% | +$10.6K | ﹤0.01% | 6727 |
|
|
2014
Q1 | $32K | Buy |
+1,000
| New | +$31.2K | ﹤0.01% | 6679 |
|
Other funds holding RVNC
Bank of America's RVNC Position: Q1 2025 in Review
Bank of America sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 150,198 shares — an estimated $457K sold.
Bank of America first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $11.6M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Bank of America reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Bank of America sold 150,198 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $457K.
- Bank of America first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
- Bank of America's Revance Therapeutics, Inc. position peaked at $11.6M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Bank of America's 13F filing for Q1 2025, filed 15 May 2025.